SMMT · NASDAQ

Summit Therapeutics Inc.

Q: How do I get SMMT news from the API?

Call GET /v1/news?tickers=SMMT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

$15.51 -0.31 (-1.99%)

Company overview

Summit Therapeutics Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of infectious diseases in the United States and Latin America. The company focuses its clinical programs on Clostridioides difficile infection (CDI). Its lead product candidate is ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials for CDI. Summit also offers SMT-738 for combating multidrug-resistant infections, primarily carbapenem-resistant Enterobacteriaceae, and the DDS-04 series for potential treatment of infections caused by Enterobacteriaceae. Founded in 2003, the company is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $12.4B
Employees: 159
Headquarters: Cambridge, MA
Website: summittxinc.com
CEO: Robert W. Duggan
Listed: March 5, 2015
P/E: -11.08
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: $0.00
Operating income: -$1.1B
EBITDA: -$1.1B
Net income: -$1.1B
EPS: -$1.40
Total assets: $491M
Total debt: $15.2M
Earnings yield: -9.03%

Revenue segmentation

By product (FY 2022)

By region (FY 2022)

Showing FY 2022

Price chart

SMMT 1D NASDAQ O15.46H15.54L15.08C15.52-0.03 (-0.19%)Vol1.04M

News

Ticker	Type	Headline	Source	Published
SMMT	Press release	Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc.	PR Newswire	Oct 23, 9:26:00 PM ET
SMMT	Press release	Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development	Business Wire	Oct 23, 4:37:00 PM ET
SMMT	Stock news	Summit Expands Ivonescimab Development Into Biliary Tract Cancer	Zacks Investment Research	Oct 22, 11:50:50 AM ET
SMMT	Stock news	Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026	Business Wire	Oct 22, 6:00:00 AM ET
SMMT	Press release	Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Akeso, Inc.	PR Newswire	Oct 21, 8:42:00 AM ET
SMMT	Stock news	Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma	Business Wire	Oct 19, 7:00:00 AM ET
SMMT	Stock news	AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment	CNBC	Oct 5, 3:44:30 PM ET
SMMT	Stock news	SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos	Zacks Investment Research	Oct 5, 11:40:40 AM ET
SMMT	Stock news	Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway	GuruFocus	Oct 2, 3:00:00 AM ET
SMMT	Stock news	Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types	Business Wire	Oct 2, 2:30:00 AM ET
SMMT	Press release	Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway	Business Wire	Oct 2, 2:30:00 AM ET
SMMT	Stock news	Robinhood Traders Just Went on Their Biggest Buying Binge Ever	Benzinga	Oct 1, 1:43:48 PM ET
SMMT	Stock news	AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets	24/7 Wall Street	Sep 30, 11:17:01 AM ET
SMMT	Press release	High-Stakes October has these Biotechs Entering Crucial Stretch	GlobeNewswire	Sep 29, 12:12:58 PM ET
SMMT	Stock news	Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment	GuruFocus	Sep 29, 11:07:00 AM ET
SMMT	Press release	HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at .	Business Wire	Sep 22, 6:00:00 AM ET
SMMT	Stock news	Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients	Business Wire	Sep 15, 6:00:00 AM ET
SMMT	Stock news	Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu	GuruFocus	Sep 13, 8:00:00 AM ET
SMMT	Press release	Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China	Business Wire	Sep 13, 7:00:00 AM ET
SMMT	Stock news	SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China	Zacks Investment Research	Sep 4, 11:53:24 AM ET

FAQ

Questions about Summit Therapeutics Inc.

What does Summit Therapeutics Inc. do?

What is SMMT's market cap?

Summit Therapeutics Inc. (SMMT) is a listed stock with a live quote. The latest market cap on this page is $12.4B.

Where is Summit Therapeutics Inc. headquartered?

Summit Therapeutics Inc. is headquartered in Cambridge, MA.

How do I get SMMT news from the API?

Call GET /v1/news?tickers=SMMT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

How far back does SMMT news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for SMMT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.

Is the SMMT price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs